Feasibility study of ambulatory continuous infusion of 5-fluorouracil followed by cisplatin through hepatic artery for metastatic colorectal cancer.

Baoli Qin, Ken Kato, Kenji Mitsugi, Minoru Nakamura, Risa Tanaka, Eishi Baba, hiroshi ariyama, Toshiro Kuroiwa, Mine Harada, Shuji Nakano

研究成果: ジャーナルへの寄稿記事

3 引用 (Scopus)

抄録

PURPOSE: A great synergy has been reported in a number of preclinical studies when 5-fluorouracil (5-FU) precedes cisplatin (CDDP). The objective of this study was to determine the feasibility of ambulatory continuous infusion of 5-FU followed by CDDP through hepatic artery for metastatic colorectal cancer. PATIENTS AND METHODS: Seventeen patients with unresectable liver metastases, who underwent primary tumor resection, were treated with 5-FU (450 mg/m2/day) for seven consecutive days followed by CDDP (100 mg/body/week) for seven consecutive days, each administered continuously by using a balloon pump via Infuse-A-Port catheter inserted into common hepatic artery. The doses of drugs were reduced 20% in patients older than 70 years. The treatment was repeated every 4-6 weeks until disease progression. RESULTS: Of 17 assessable patients, nine patients showed PR (53%; 95% CI, 29.3-76.7%) and eight patients had SD (47%; 95% CI, 23.3-70.7%), with disease control rate of 100%. The median overall survival was 26 months (95% CI: 17.5-41 months) and TTP 14 months (95% CI: 11-20.3 months). Two patients (11.8%), who showed progression due to collateral feeding arteries, responded to HAI again after occlusion. Grade 3 toxicity included leukopenia (12%) and anemia (24%). Grade 4 toxicity was absent. Four patients (23.5%) progressed at extrahepatic sites. CONCLUSIONS: This sequential combination of 5-FU followed by CDDP through hepatic artery is active and safe in an outpatient setting, and warrants further multi-institutional study, although prevention of micrometastasis would be mandatory to further prolong overall survival.

元の言語英語
ページ(範囲)114-119
ページ数6
ジャーナルCancer chemotherapy and pharmacology
57
発行部数1
DOI
出版物ステータス出版済み - 1 1 2006

Fingerprint

Hepatic Artery
Feasibility Studies
Fluorouracil
Cisplatin
Colorectal Neoplasms
Toxicity
Disease control
Catheters
Balloons
Liver
Tumors
Vascular Access Devices
Pumps
Neoplasm Micrometastasis
Survival
Leukopenia
Disease Progression
Anemia
Pharmaceutical Preparations
Outpatients

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

これを引用

Feasibility study of ambulatory continuous infusion of 5-fluorouracil followed by cisplatin through hepatic artery for metastatic colorectal cancer. / Qin, Baoli; Kato, Ken; Mitsugi, Kenji; Nakamura, Minoru; Tanaka, Risa; Baba, Eishi; ariyama, hiroshi; Kuroiwa, Toshiro; Harada, Mine; Nakano, Shuji.

:: Cancer chemotherapy and pharmacology, 巻 57, 番号 1, 01.01.2006, p. 114-119.

研究成果: ジャーナルへの寄稿記事

Qin, Baoli ; Kato, Ken ; Mitsugi, Kenji ; Nakamura, Minoru ; Tanaka, Risa ; Baba, Eishi ; ariyama, hiroshi ; Kuroiwa, Toshiro ; Harada, Mine ; Nakano, Shuji. / Feasibility study of ambulatory continuous infusion of 5-fluorouracil followed by cisplatin through hepatic artery for metastatic colorectal cancer. :: Cancer chemotherapy and pharmacology. 2006 ; 巻 57, 番号 1. pp. 114-119.
@article{8940dbd4aceb458d8f9913fae9a9f48e,
title = "Feasibility study of ambulatory continuous infusion of 5-fluorouracil followed by cisplatin through hepatic artery for metastatic colorectal cancer.",
abstract = "PURPOSE: A great synergy has been reported in a number of preclinical studies when 5-fluorouracil (5-FU) precedes cisplatin (CDDP). The objective of this study was to determine the feasibility of ambulatory continuous infusion of 5-FU followed by CDDP through hepatic artery for metastatic colorectal cancer. PATIENTS AND METHODS: Seventeen patients with unresectable liver metastases, who underwent primary tumor resection, were treated with 5-FU (450 mg/m2/day) for seven consecutive days followed by CDDP (100 mg/body/week) for seven consecutive days, each administered continuously by using a balloon pump via Infuse-A-Port catheter inserted into common hepatic artery. The doses of drugs were reduced 20{\%} in patients older than 70 years. The treatment was repeated every 4-6 weeks until disease progression. RESULTS: Of 17 assessable patients, nine patients showed PR (53{\%}; 95{\%} CI, 29.3-76.7{\%}) and eight patients had SD (47{\%}; 95{\%} CI, 23.3-70.7{\%}), with disease control rate of 100{\%}. The median overall survival was 26 months (95{\%} CI: 17.5-41 months) and TTP 14 months (95{\%} CI: 11-20.3 months). Two patients (11.8{\%}), who showed progression due to collateral feeding arteries, responded to HAI again after occlusion. Grade 3 toxicity included leukopenia (12{\%}) and anemia (24{\%}). Grade 4 toxicity was absent. Four patients (23.5{\%}) progressed at extrahepatic sites. CONCLUSIONS: This sequential combination of 5-FU followed by CDDP through hepatic artery is active and safe in an outpatient setting, and warrants further multi-institutional study, although prevention of micrometastasis would be mandatory to further prolong overall survival.",
author = "Baoli Qin and Ken Kato and Kenji Mitsugi and Minoru Nakamura and Risa Tanaka and Eishi Baba and hiroshi ariyama and Toshiro Kuroiwa and Mine Harada and Shuji Nakano",
year = "2006",
month = "1",
day = "1",
doi = "10.1007/s00280-005-0021-8",
language = "English",
volume = "57",
pages = "114--119",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Feasibility study of ambulatory continuous infusion of 5-fluorouracil followed by cisplatin through hepatic artery for metastatic colorectal cancer.

AU - Qin, Baoli

AU - Kato, Ken

AU - Mitsugi, Kenji

AU - Nakamura, Minoru

AU - Tanaka, Risa

AU - Baba, Eishi

AU - ariyama, hiroshi

AU - Kuroiwa, Toshiro

AU - Harada, Mine

AU - Nakano, Shuji

PY - 2006/1/1

Y1 - 2006/1/1

N2 - PURPOSE: A great synergy has been reported in a number of preclinical studies when 5-fluorouracil (5-FU) precedes cisplatin (CDDP). The objective of this study was to determine the feasibility of ambulatory continuous infusion of 5-FU followed by CDDP through hepatic artery for metastatic colorectal cancer. PATIENTS AND METHODS: Seventeen patients with unresectable liver metastases, who underwent primary tumor resection, were treated with 5-FU (450 mg/m2/day) for seven consecutive days followed by CDDP (100 mg/body/week) for seven consecutive days, each administered continuously by using a balloon pump via Infuse-A-Port catheter inserted into common hepatic artery. The doses of drugs were reduced 20% in patients older than 70 years. The treatment was repeated every 4-6 weeks until disease progression. RESULTS: Of 17 assessable patients, nine patients showed PR (53%; 95% CI, 29.3-76.7%) and eight patients had SD (47%; 95% CI, 23.3-70.7%), with disease control rate of 100%. The median overall survival was 26 months (95% CI: 17.5-41 months) and TTP 14 months (95% CI: 11-20.3 months). Two patients (11.8%), who showed progression due to collateral feeding arteries, responded to HAI again after occlusion. Grade 3 toxicity included leukopenia (12%) and anemia (24%). Grade 4 toxicity was absent. Four patients (23.5%) progressed at extrahepatic sites. CONCLUSIONS: This sequential combination of 5-FU followed by CDDP through hepatic artery is active and safe in an outpatient setting, and warrants further multi-institutional study, although prevention of micrometastasis would be mandatory to further prolong overall survival.

AB - PURPOSE: A great synergy has been reported in a number of preclinical studies when 5-fluorouracil (5-FU) precedes cisplatin (CDDP). The objective of this study was to determine the feasibility of ambulatory continuous infusion of 5-FU followed by CDDP through hepatic artery for metastatic colorectal cancer. PATIENTS AND METHODS: Seventeen patients with unresectable liver metastases, who underwent primary tumor resection, were treated with 5-FU (450 mg/m2/day) for seven consecutive days followed by CDDP (100 mg/body/week) for seven consecutive days, each administered continuously by using a balloon pump via Infuse-A-Port catheter inserted into common hepatic artery. The doses of drugs were reduced 20% in patients older than 70 years. The treatment was repeated every 4-6 weeks until disease progression. RESULTS: Of 17 assessable patients, nine patients showed PR (53%; 95% CI, 29.3-76.7%) and eight patients had SD (47%; 95% CI, 23.3-70.7%), with disease control rate of 100%. The median overall survival was 26 months (95% CI: 17.5-41 months) and TTP 14 months (95% CI: 11-20.3 months). Two patients (11.8%), who showed progression due to collateral feeding arteries, responded to HAI again after occlusion. Grade 3 toxicity included leukopenia (12%) and anemia (24%). Grade 4 toxicity was absent. Four patients (23.5%) progressed at extrahepatic sites. CONCLUSIONS: This sequential combination of 5-FU followed by CDDP through hepatic artery is active and safe in an outpatient setting, and warrants further multi-institutional study, although prevention of micrometastasis would be mandatory to further prolong overall survival.

UR - http://www.scopus.com/inward/record.url?scp=33644677705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644677705&partnerID=8YFLogxK

U2 - 10.1007/s00280-005-0021-8

DO - 10.1007/s00280-005-0021-8

M3 - Article

VL - 57

SP - 114

EP - 119

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -